Skip to main
NRSN
NRSN logo

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics Ltd demonstrates a promising outlook driven by the successful results of its Phase 2b PARADIGM study, which showed a statistically significant 29.2% slowing of disease progression in patients treated with PrimeC. The company’s focus on neurodegenerative diseases and the favorable safety profile of its therapy, bolstered by biomarker-driven evidence of target engagement, enhance its potential for strategic partnerships, especially in North America and Europe. With the convergence of these clinical milestones and the opportunity for non-dilutive capital through regional commercial partnerships, NeuroSense is well-positioned for future growth and collaboration opportunities.

Bears say

NeuroSense Therapeutics Ltd is experiencing tightening cash flows, indicating potential liquidity challenges that could impair operational capabilities. The need for a capital raise suggests that the company may face difficulties in funding its ongoing development programs, such as PrimeC, which targets neurodegenerative diseases. These financial pressures could hinder the company's ability to advance its research and development efforts, negatively impacting investor sentiment and overall stock performance.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.